1. The study evaluated the efficacy of amisulpride, fluoxetine and clomipramine at the beginning of the re-feeding phase of the treatment of restricting anorexia nervosa according to DSM-IV criteria. 2. 13 patients, mean weight 37.61 kg ± 9.80 SD, were treated with clomipramine at a mean dosage of 57.69 mg ± 25.79 SD; 10 patients, mean weight 40.90 kg ± 6.98 SD, were treated with fluoxetine at a mean dosage of 28.00 mg ± 10.32 SD; 12 patients, mean weight 38.41 kg ± 8.33 SD, were treated with amisulpride at a mean dosage of 50.00 mg ± 0.00 SD. 3. Clinical evaluation was carried out under single-blind condition at basal time and after three months by a structured clinical interview, the Eating Disorder Interview based on Long Interval Follow-up Evaluation (LIFE II BEI). 4. Patients treated with amisulpride showed a more significant increase (p=O.O16) of mean weight. Concerning weight phobia, body image disturbance and amenorrhoea, no significant difference resulted.
|Number of pages||11|
|Journal||Progress in Neuro-Psychopharmacology and Biological Psychiatry|
|Publication status||Published - 2001|
- Re-feeding treatment
- Restricting anorexia nervose
ASJC Scopus subject areas
- Biological Psychiatry